Cargando…

Systematic review and meta‐analysis of intravenous iron‐carbohydrate complexes in HFrEF patients with iron deficiency

Iron deficiency (ID) is a common co‐morbidity in patients with heart failure (HF). The present meta‐analysis evaluates the effect of intravenous (IV) iron‐carbohydrate complex supplementation in patients with HF with reduced ejection fraction (HFrEF) and ID/iron deficiency anaemia (IDA). Randomized...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sindone, Andrew, Doehner, Wolfram, Comin‐Colet, Josep
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871661/ https://www.ncbi.nlm.nih.gov/pubmed/36178088 http://dx.doi.org/10.1002/ehf2.14177

Ejemplares similares

Budget Impact of Intravenous Iron Therapy with Ferric Carboxymaltose in Patients with Chronic Heart Failure with Reduced Ejection Fraction (HFrEF) and Iron Deficiency in Switzerland
por: Brock, Elisabeth, et al.
Publicado: (2022)

Benefits of peritoneal ultrafiltration in HFpEF and HFrEF patients
por: Grossekettler, Leonie, et al.
Publicado: (2020)

Locomotor and respiratory muscle abnormalities in HFrEF and HFpEF
por: Mangner, Norman, et al.
Publicado: (2023)

Different determinants of exercise capacity in HFpEF compared to HFrEF
por: Batalli, Arlind, et al.
Publicado: (2017)

Iron deficiency in chronic heart failure: case‐based practical guidance
por: Lam, Carolyn S. P., et al.
Publicado: (2018)

Aiming at harmony. Comparing and contrasting International HFrEF Guidelines
por: Tomasoni, Daniela, et al.
Publicado: (2022)

Getting ahead of the game: in-hospital initiation of HFrEF therapies
por: Biegus, Jan, et al.
Publicado: (2022)

Iron therapy and severe arrhythmias in HFrEF: rationale, study design, and baseline results of the RESAFE‐HF trial
por: Bakogiannis, Constantinos, et al.
Publicado: (2023)

Mortality and Morbidity in HFrEF, HFmrEF, and HFpEF Patients with Diabetes in the Middle East
por: Al-Jarallah, Mohammed, et al.
Publicado: (2020)

Association of Depression Symptoms and Biomarkers of Risk on Clinical Outcomes in HFrEF
por: Sherwood, Andrew, et al.
Publicado: (2023)

A horse of a different colour: distinct mechanisms of HFpEF and HFrEF
por: Louch, William E.
Publicado: (2020)

Neprilysin in HFrEF: Differential Regulation of Tissue Versus Circulating Neprilysin
por: Chen, Horng H., et al.
Publicado: (2020)

Empagliflozin and HFrEF: Known and Possible Benefits of NHE1 Inhibition
por: Jun, Seungho, et al.
Publicado: (2019)

Corrigendum to: Aiming at harmony. Comparing and contrasting International HFrEF Guidelines
Publicado: (2023)

Quality of life questionnaire predicts poor exercise capacity only in HFpEF and not in HFrEF
por: Ahmeti, Artan, et al.
Publicado: (2017)

Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes
por: Kristensen, Søren L., et al.
Publicado: (2017)

Myocardial phenotypes and dysfunction in HFpEF and HFrEF assessed by echocardiography and cardiac magnetic resonance
por: Berlot, Bostjan, et al.
Publicado: (2019)

Disparate Clinical Characteristics and Prognosis of HFpEF versus HFrEF Phenotype of Diabetic Cardiomyopathy
por: Li, Zheng, et al.
Publicado: (2023)

Practical Guidance for Diagnosing and Treating Iron Deficiency in Patients with Heart Failure: Why, Who and How?
por: Sindone, Andrew, et al.
Publicado: (2022)

Large Animal Models of Heart Failure With Reduced Ejection Fraction (HFrEF)
por: Spannbauer, Andreas, et al.
Publicado: (2019)

Plasma Neprilysin Displays No Relevant Association With Neurohumoral Activation in Chronic HFrEF
por: Prausmüller, Suriya, et al.
Publicado: (2020)

FGF-23 is a biomarker of RV dysfunction and congestion in patients with HFrEF
por: Benes, Jan, et al.
Publicado: (2023)

Meta‐analysis of the effects of four factors on the efficacy of SGLT2 inhibitors in patients with HFrEF
por: Qiu, Mei, et al.
Publicado: (2021)

Prognostic Benefit of New Drugs for HFrEF: A Systematic Review and Network Meta-Analysis
por: Pagnesi, Matteo, et al.
Publicado: (2022)

Effect of pueraria on left ventricular remodelling in HFrEF: A systematic review and meta-analysis
por: Shi, Lipeng, et al.
Publicado: (2023)

The vasculature in HFpEF vs HFrEF: differences in contractile protein expression produce distinct phenotypes
por: Lyle, Melissa A., et al.
Publicado: (2019)

Ubiquitin‐proteasome‐system and enzymes of energy metabolism in skeletal muscle of patients with HFpEF and HFrEF
por: Adams, Volker, et al.
Publicado: (2021)

Circulating Relaxin-1 Level Is a Surrogate Marker of Myocardial Fibrosis in HFrEF
por: Simon, Judit, et al.
Publicado: (2019)

Sacubitril/valsartan in HFrEF – Should the aces up our sleeves be played earlier?
por: Boehmer, Andreas A., et al.
Publicado: (2019)

The association between ivabradine and adverse cardiovascular events in acute decompensated HFrEF patients
por: Liao, Chia‐Te, et al.
Publicado: (2021)

Echocardiographic Parameters as Predictors for the Efficiency of Resynchronization Therapy in Patients with Dilated Cardiomyopathy and HFrEF
por: Pescariu, Silvius-Alexandru, et al.
Publicado: (2021)

Sacubitril/Valsartan vs. Standard Medical Therapy on Exercise Capacity in HFrEF Patients
por: Campanile, Alfonso, et al.
Publicado: (2023)

Qili Qiangxin Capsule Combined With Sacubitril/Valsartan for HFrEF: A Systematic Review and Meta-Analysis
por: Xiang, Qian, et al.
Publicado: (2022)

Testosterone deficiency independently predicts mortality in women with HFrEF: insights from the T.O.S.CA. registry
por: Marra, Alberto M., et al.
Publicado: (2022)

Cellular and Molecular Differences between HFpEF and HFrEF: A Step Ahead in an Improved Pathological Understanding
por: Simmonds, Steven J., et al.
Publicado: (2020)

The four pillars of HFrEF therapy: is it time to treat heart failure regardless of ejection fraction?
por: Docherty, Kieran F, et al.
Publicado: (2022)

A Practical Guide for the Treatment of Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF)
por: Reed, Brent N, et al.
Publicado: (2015)

The prevalence, predictors, and outcomes of spontaneous echocardiographic contrast or left ventricular thrombus in patients with HFrEF
por: Zhou, Xiaodong, et al.
Publicado: (2021)

ARNI in HFrEF—One-Centre Experience in the Era before the 2021 ESC HF Recommendations
por: Niemiec, Rafał, et al.
Publicado: (2022)

Chronic Kidney Disease Increases Risk of Incident HFrEF Following Percutaneous Coronary Intervention
por: Lai, Wenguang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2ka24ng2dh2n0pruvv5s1nklne